01—Abstract
Summary
Summary of the 8-K filed April 17, 2025. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated (INSM) filed a Form 8-K under Item 5.02 reporting that J.
Drayton Wise resigned as the Company's Chief Commercial Officer, effective immediately, as notified on April 16, 2025. The filing states that his resignation was for personal and medical reasons and was not related to the Company's financial or operating results or to any disagreements with the Company regarding its operations, policies, or practices. In connection with the departure, Mr. Wise entered into a consulting agreement with the Company dated April 16, 2025.
He will be reasonably available to provide consulting services through December 31, 2025, with automatic extension for two three-month periods unless terminated by mutual agreement. His consulting fee is $30,000a per month during the initial period and $20,000 per month during any extension period, conditioned on his compliance with the agreement.
Mr. Wise's outstanding equity awards will continue to vest during the consulting period. His stock options will remain exercisable, to the extent vested, until the earlier of three months after the last day of his service relationship with the Company and the original 10-year expiration date.
02—Key points
Key Highlights
- J. Drayton Wise resigned as Chief Commercial Officer, effective immediately, with notice given on April 16, 2025.
- The filing states the resignation was for personal and medical reasons and was not related to the Company's financial or operating results or to any disagreements with the Company.
- Mr. Wise will provide consulting services under a consulting agreement dated April 16, 2025, reasonably available through December 31, 2025.
- The consulting agreement allows automatic extension for two three-month periods unless terminated by mutual agreement.
- Consulting fees are $30,000 per month during the initial consulting period and $20,000 per month during each extension period.
- Outstanding equity awards will continue to vest during the consulting period, and vested stock options remain exercisable until the earlier of three months after the service relationship ends or the original 10-year expiration date.
03—Questions
Frequently Asked Questions
Why did the Chief Commercial Officer resign?
The filing states that J. Drayton Wise resigned for personal and medical reasons. It also states the resignation was not related to the Company's financial or operating results or to any disagreements or concerns regarding its operations, policies, or practices.
Will the former Chief Commercial Officer remain involved with the Company?
Yes. Under a consulting agreement dated April 16, 2025, Mr. Wise will be reasonably available to provide consulting services through December 31, 2025, subject to automatic extension for two three-month periods unless the agreement is terminated by mutual agreement.
How will Mr. Wise be compensated after leaving the executive role?
Conditioned on his compliance with the Consulting Agreement, he will receive $30,000 per month during the Initial Consulting Period and $20,000 per month during each Extension Period. His outstanding equity awards will also continue to vest during the Consulting Period.
What happens to Mr. Wise's stock options?
In accordance with the Company's equity incentive plans and his grant agreements, his stock options will continue to be exercisable, to the extent vested, until the earlier of three months following the last day of his service relationship with the Company and the original 10-year expiration date for such vested options.
04—Continue